[영어] - [한영]

등록자 : 관리자

업데이트 : 2020. 5. 31. 오전 7:10:05

2001후65

Korean Supreme Court

Trial against the Dismissal of Amendment (Pfizer, Inc.)


【Case No.】Supreme Court 2001 Hu 65 (Decided on November 30, 2001)

【Gist of Judgement】

As for a use invention for a medicament which requires the description of the pharmacological effects in the specification, if there is not a particular circumstance that the pharmacological mechanism showing the pharmacological effects has been clearly illuminated prior to the filing of the invention, the use invention is not regarded as being completed nor complying with the description requirements of the specification unless the specification includes working examples indicating pharmacological data, etc. showing that specific materials have such pharmacological effects, or is described clearly enough to take the place of them. Therefore, it is a change in the subject matter of the invention beyond the scope of the disclosure of the specification to add working examples not described in the original specification by making an amendment later.

Korean Supreme Court

Trial against the Final Rejection (Glaxo Group Ltd.)

【Case No.】Supreme Court 99 Hu 2396 (Decided on November 13, 2001)

【Gist of Judgement】

1. In case of the present invention claiming as the subject matter that when ondansetron and dexamethasone known as antiemetic are co-administered, they have a synergistic antiemetic effect than that of each material; if the pharmacological mechanism that the combination has a synergistic effect than that of ondansetron is not disclosed, the invention is not regarded as describing the effect so clearly that a person skilled in the art can easily understand it unless the specification describes how synergistic antiemetic effect the combination has quantitatively or numerically by comparative examples, etc. As a result, it is not considered that the present invention describes the effect of the invention so clearly as to be easily carried out by a person skilled in the art.

2. The present invention describes only the general dosage, administration method and the like for each of ondansetron and dexamethasone known as antiemetic, but mentions neither the combining ratio of ondansetron and dexamethasone nor grounds for dosage and administration number nor the correlation with the pharmacological effect. Thus, a person skilled in the art cannot confirm the effect of the present invention by the specification.

In addition, although working examples must include examples using the pharmaceutical composition of the present invention as an antiemetic, they describe only the examples for preparing ondansetron and the composition.

3. There are no grounds in the plaintiff's argument that although the pharmacological effect of the invention is not sufficiently confirmed in the specification, since experimental data were submitted during the examination and trial proceedings, the present invention does not violate the description requirements of the specification.

4. The description requirements of the specification should be judged individually according to a specific invention, and not bound by other examination cases or judicial precedents. Furthermore, foreign examination cases under the different legal system and practices cannot be considered.